Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Further characterization of a ¹³C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy.

Journal of breath research - 20 Apr 2015

Opdam F L, Modak A S, Gelderblom H, Guchelaar H J

Abstract excerpt

In a previous study, we found that the CYP2D6 phenotype determined by (13)C-dextromethorphan breath test (DM-BT) might be used to predict tamoxifen treatment outcome in breast cancer patients in the adjuvant setting. However, large variation in the delta-over-baseline (DOB) values was observed in the extensive metabolizer predicted phenotype group based on single point measures. In the present work we aimed to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Hormonal
Share to Breath Tests

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Carbon Isotopes

Share to Cytochrome P-450 CYP2D6

Share to Dextromethorphan

Share to Excitatory Amino Acid Antagonists

Share to Reproducibility of Results

Share to Tamoxifen

Source

Identifiers

PMID: 25891764
DOI: 10.1088/1752-7155/9/2/026003

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Further characterization of a ¹³C-dextromethorphan breath test for CYP2D6 phenotyping in breast cancer patients on tamoxifen therapy.PMID 25891764Read ↗

Breath tests to phenotype drug disposition in oncology.Semantic proximity Read ↗

The use of the 13C-dextromethorphan breath test for phenotyping CYP2D6 in breast cancer patients using tamoxifen: association with CYP2D6 genotype and serum endoxifen levels.Semantic proximity Read ↗

Evaluation of a [13C]-dextromethorphan breath test to assess CYP2D6 phenotype.Semantic proximity Read ↗

Evaluation of CYP2D6 enzyme activity using a 13C-dextromethorphan breath test in women receiving adjuvant tamoxifen.Semantic proximity Read ↗

Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.Semantic proximity Read ↗

CYP2D6 phenotyping with dextromethorphan.Semantic proximity Read ↗

Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.Semantic proximity Read ↗

Liquid Chromatography-Tandem Mass Spectrometry Quantification of Diet-Derived CYP2D6 Biomarkers for Clinical Phenotyping in Japanese Subjects.Semantic proximity Read ↗

Influence of CYP2D6 and CYP3A4 Phenotypes, Drug Interactions, and Vitamin D Status on Tamoxifen Biotransformation.Semantic proximity Read ↗

Alternative methods for CYP2D6 phenotyping: comparison of dextromethorphan metabolic ratios from AUC, single point plasma, and urine.Semantic proximity Read ↗

Analysis of pharmacokinetic parameters for assessment of dextromethorphan metabolic phenotypes.Semantic proximity Read ↗

Endoxifen levels and its association with CYP2D6 genotype and phenotype: evaluation of a southern Brazilian population under tamoxifen pharmacotherapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.